If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCRX.L Regulatory News (CRX)

  • There is currently no data for CRX

Directorate Change

25 Feb 2009 07:00

RNS Number : 8182N
Cyprotex PLC
25 February 2009
 



25 February 2009

Cyprotex PLC ('Cyprotex' or the 'Company')

Directorate changes

Cyprotex PLC (AIM: CRX) today announces the resignation of David Evans as a Non-executive Director of the Company with immediate effect and the appointment of John Dootson as Chief Financial Officer effective from 2 March 2009.

Commenting on the directorate changes, Steve Harris, Chairman of Cyprotex said: 

"David has made a significant contribution to the Company as a Non-executive Director and the Board would like to thank him for his contribution to the Company and wish him well with his future endeavours. 

The Company is very pleased to appoint John Dootson as Chief Financial Officer. John has been associated with the Company for over four years as a consultant Financial Controller and therefore has intimate knowledge of the Company's business and finances. He brings to the Company wide ranging financial expertise gained in both industry and private practice"

Notes for Editors: 

John Dootson, aged 47, has 25 years experience in both professional practice and in industry. Trained with Tenon and Ernst & Young, John has extensive managerial experience in major accounting practices and has worked on a wide range of projects including London Stock Exchange flotations and circulars, corporate governance, company acquisitions and disposals and specialist advice to growing SMEs. John has also worked in a number of roles in Industry at Financial Controller and Director level, including seven years within the senior head office finance team of BTP plc, a former FTSE250 specialty chemical manufacturer with over 50 sites worldwide prior to its sale to Clariant AG for £1.1bn.

John is a Fellow of the Institute of Chartered Accountants in England and Wales and for the last four years he has assisted Cyprotex in a management consultative role that has included all aspects of finance and reporting.

The following information relating to Mr. Dootson is provided in compliance with the provisions of Rule 17, Schedule Two, paragraph (g) of the AIM Rules for Companies

 

Full name and age: John Kevin Dootson, age 47.

Present directorships: Downham Mayer Clarke Limited

 

Directorships during the past five years:  Downham Mayer Clarke Limited

Mr. Dootson has not been a director of any company which has been wound up or placed in administration or receivership.

Mr. Dootson holds no shares in the Company. 

There are no further disclosures to be made in respect of Mr. Dootson under the provisions of Rule 17, Schedule Two, paragraph (g) of the AIM Rules for Companies.

 

Enquiries:

Cyprotex PLC

 

Tony BaxterCEO 

01625 505100

Mark WarburtonCompany Secretary

 

Noble & Company Limited

 

John Llewellyn-Lloyd 

 02077632200

Sam Reynolds

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOATIMATMMITBJL
Date   Source Headline
10th Oct 20142:36 pmRNSShare Allotment CLN Final
9th Oct 20147:00 amRNSExpansion of Drug Transporter Capabilities
1st Oct 20147:00 amRNSExpansion of Toxicology Capabilities
9th Sep 20147:00 amRNSLaunch of KeratinoSensTM Service
4th Sep 20147:00 amRNSCyprotex joins CiPA initiative
29th Aug 20144:28 pmRNSListing of Loan Notes on Cayman Stock Exchange
28th Aug 20147:00 amRNSInterim Results 2014
21st Aug 20147:00 amRNSListing of Loan Notes on Cayman Stock Exchange
14th Aug 20143:30 pmRNSHolding(s) in Company
24th Jul 201412:15 pmRNSResult of AGM, GM & Further re Share Consolidation
3rd Jul 20147:00 amRNSProposed Share Consolidation & Notice of GM
1st Jul 20147:00 amRNSExpansion of Bioanalytical Capabilities
4th Jun 201411:44 amRNSDirector/PDMR Shareholding
16th Apr 201411:31 amRNSGrant of Options
25th Mar 20147:00 amRNSFinal Results
13th Mar 20144:57 pmRNSHolding(s) in Company
28th Jan 201410:46 amRNSGrant Options
28th Jan 201410:15 amRNSgrant of options
27th Jan 20144:52 pmRNSHolding(s) in Company
27th Jan 20144:19 pmRNSHolding(s) in Company
23rd Jan 20147:01 amRNSExecutive option scheme
23rd Jan 20147:00 amRNSTrading Update
2nd Jan 20147:00 amRNSAcquisition of CeeTox
19th Dec 20139:56 amRNSHolding(s) in Company
25th Nov 20139:48 amRNSDirector Dealing
5th Nov 20131:33 pmRNSReplacement: Holding(s) in Company
5th Nov 20139:44 amRNSHolding(s) in Company
5th Nov 20139:36 amRNSHolding(s) in Company
1st Oct 20131:36 pmRNSHolding(s) in Company
30th Sep 201311:43 amRNSHolding(s) in Company
26th Sep 201310:22 amRNSResult of GM & Board changes
3rd Sep 20137:00 amRNSPublication of Circular
21st Aug 20137:00 amRNSSubscription Agreement
15th Aug 20139:04 amRNSHolding(s) in Company
7th Aug 20137:00 amRNSHalf Yearly Report
24th Jul 20131:39 pmRNSDirectorate Change
18th Jul 20137:00 amRNSLaunch of new eCiphrNeuro service
17th Jul 20133:08 pmRNSResult of AGM
11th Jul 20137:00 amRNSLaunch of New Toxicity Guide
4th Jul 201310:09 amRNSHolding(s) in Company
2nd Jul 20132:09 pmRNSHolding(s) in Company
27th Jun 20134:36 pmRNSDirector/PDMR Shareholding
27th Jun 20132:30 pmRNSHolding(s) in Company
27th Jun 20132:30 pmRNSHolding(s) in Company
27th Jun 20132:30 pmRNSHolding(s) in Company
20th Jun 20137:00 amRNSTrading update
4th Jun 20137:00 amRNSIssue of Equity
21st May 20132:06 pmRNSHolding(s) in Company
21st May 20132:05 pmRNSHolding(s) in Company
1st May 20137:00 amRNSContract with U.S. EPA

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.